

Institutional Biosafety Committee MEETING MINUTES

Institution: Old Dominion University

Meeting Date: July 29, 2025

Meeting Time: 1:00 PM-3:00 PM

Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform

IBC Members Present:

.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice-Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Patrick Sachs (IBC Member)
Shawn Sarauw (IBC Member)
Wayne Hynes (IBC Member/Animal Expert)
Danielle Dady (Non-Affiliated Member)
Megan Scott (Non-Affiliated Member)

Quorum: Present

Other Individuals in Attendance:

Srivenkat Kosuri (Manager Compliance)

Call to Order: The IBC Chair called the meeting to order at 1:05 PM

Conflict of Interest: Conflict declared and recused from deliberations.
Please see under votes for each protocol for details.

Review & Approval of previous meeting minutes:

June 2025, meeting minutes are approved as written unanimously.

Review of Prior Business: None

New IBC Registrations

PI Name: David Gauthier, Ph.D.

Reference Number/Title:

[2334120-1/25-005]/ BIOL454/455 class IBC

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

This submission of new project has received full committee review for risk assessment. After the required modifications, and it was approved.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

N/A

Biosafety Level Assignment:

BSL1

IBC Vote:

This new protocol submission has received full committee review and approval.

Total = 9; For = 9; Opposed = 0; Abstained = 0; Recused = 0.

Continuing Review of Protocols, Closures, and Amendments:

PI Name: Erin Purcell, Ph.D.

Reference Number/Title:

[1756703-15/21-004] Mechanisms of Stress Survival in Gram Positive Bacteria

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved to continue the protocol.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None required.

Biosafety Level Assignment

BSL1 and BSL2

IBC Vote This submission has received full committee review and approval after clarifications.

Total = 9; For = 8; Opposed = 0; Abstained = 0; Recused = 1.

Dr. Erin Purcell, recused from deliberations and approval voting for her protocol due to conflict declared.

PI Name: James Lee, Ph.D.

Reference Number/Title: [2212354-8/24-001] GE Microbials and Cells Biosafety Assessment Research

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved to continue the protocol.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

N/A

Biosafety Level Assignment

BSL1 and BSL2

IBC Vote

This submission of Continuing Review has received a full committee reviewed and approval.

Total = 9; For = 8; Opposed = 0; Abstained = 0; Recused = 1.

Dr. Lesley Greene recused from deliberations and approval voting for the protocol due to conflict declared.

PI Name: Michelle King, Ph.D.

Reference Number/Title:

[2219699-3/24-017] BIO 122 CURE; Tiny Earth

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved to continue the protocol.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

None Required

Biosafety Level Assignment

BSL1

IBC Vote

This submission of Continuing Review has received a full committee review and approval.
Total = 9; For = 9; Opposed = 0; Abstained = 0; Recused = 0.

PI Name: Michael Stacey, Ph.D.

Reference Number/Title: [2207278-4/24-015] "Mitochondrial Epigenetic Processes and Transfers in Chondrosarcoma Cancers with Mutant IDH2"

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved to continue the protocol...

Training:

N/A

Occupational Health Representative review (if applicable):

N/A

Biosafety Level Assignment

N/A

IBC Vote

Continuing Review/ reviewed by the full committee and approved.

Total = 9; For = 8; Opposed = 0; Abstained = 0; Recused =1.

PI Name: Patrick Sachs, Ph.D.

Reference Number/Title: [2187930-3/24-009] Isolation/generation, culture, and transplantation of Cell lines/ECMs

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

The committee reviewed risk assessment and approved to continue the protocol..

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):

N/A

Biosafety Level Assignment

BSL-2

IBC Vote

Continuing Review was reviewed by the full committee and approved

Total =9; For = 8; Opposed = 0; Abstained = 0; Recused = 1.

Dr. Patrick Sachs recused from deliberations and approval voting for the protocol due to conflict declared.

PI Name: Michelle King, Ph.D.

Reference Number/Title:

[2029438-7/23-003] Biol 317 class.

NIH Guidelines Section: N/A

Risk Assessment and Discussion:

This submission of Continuing Review/Progress Report has received full committee review for risk assessment and approved.

Training:

As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable): N/A

Biosafety Level Assignment: BSL-2

IBC Vote

Continuing Review/Progress Report has received full committee review and approval.

Total = 9; For = 9; Opposed = 0; Abstained = 0; Recused = 0.

PI Name: Lisa Shollenberger, Ph.D.

Reference Number/Title:

[2195748-3/24-010] Overcoming vaccine failure: biosafety of vaccine vectors

NIH Guidelines Section: Section III-F

Risk Assessment and Discussion:

This submission of Continuing Review has received a full committee review for risk assessment and approved

Training:

As per NIH Guidelines, biosafety and laboratory safety training for laboratory staff was completed

Occupational Health Representative review (if applicable): N/A

Biosafety Level Assignment: BSL-2

IBC Vote

Continuing Review has received a full committee review and approval.

Total = 9; For = 8 Opposed = 0; Abstained = 1; Recused = 1.

Dr. Wayne Hynes recused from deliberations and approval voting for the protocol due to conflict declared.

PI Name: Barbara Hargrave, Ph.D.

Reference Number/Title:

[2207257-3/24-013] PRP and Cell Culture

NIH Guidelines Section: N/A

Risk Assessment and Discussion:
N/A

Training:
N/A

Occupational Health Representative review (if applicable): N/A

Biosafety Level Assignment: BSL-1

IBC Vote

Closure/Final Report has received full committee review and approval.
Total = 9; For = 9 Opposed = 0; Abstained = 0; Recused = 0.

New Business/Additional Topics: None

Review of Incidents: None

Inspections/Ongoing Oversight: None

Public Comments (If Any): None

Adjournment: The IBC Chair moved to adjourn the meeting at 3:00 PM.

The next meeting scheduled is for August 26, 2025, at 1 PM via a Zoom meeting.